Literature DB >> 16790647

The comparative effects of sevoflurane versus isoflurane on cerebrovascular carbon dioxide reactivity in patients with diabetes mellitus.

Yuji Kadoi1, Ken-Ichiro Takahashi, Shigeru Saito, Fumio Goto.   

Abstract

The use of volatile anesthetics has been reported to alter cerebrovascular carbon dioxide (CO2) reactivity. We examined the comparative effects of sevoflurane versus isoflurane on cerebrovascular CO2 reactivity in 40 patients with diabetes mellitus. Anesthesia was maintained with either 1.0 minimum alveolar anesthetic concentration of sevoflurane or 1.0 minimum alveolar anesthetic concentration of isoflurane in 33% oxygen and 67% nitrous oxide. A 2.5-MHz pulsed transcranial Doppler probe was attached to the patient's head at the right temporal window for continuous measurement of mean blood flow velocity in the middle cerebral artery. After establishing baseline middle cerebral artery velocity values and cardiovascular hemodynamics, we increased end-tidal CO2 by decreasing ventilatory frequency by 2-5 breaths/min and repeated the measurements. These were then used to calculate absolute and relative CO2 reactivity. Absolute CO2 reactivity was less in insulin-treated patients with either sevoflurane or isoflurane compared with those patients on oral antidiabetic drugs or dietary therapy (sevoflurane group: diet = 2.6 +/- 0.6; oral antidiabetic drug = 2.5 +/- 0.8; insulin = 1.6 +/- 0.8*; isoflurane group: diet = 3.3 +/- i0.7; oral antidiabetic drug = 3.4 +/- 0.7; insulin = 1.9 +/- 0.7* cm.s(-1).mm Hg(-1); *P < 0.05, respectively). Relative CO2 reactivity showed a similar pattern in the diet-controlled and oral antidiabetic groups, absolute and relative CO2 reactivities were lower with sevoflurane versus isoflurane. Hence, we conclude that cerebrovascular CO2 reactivity in insulin-dependent patients is impaired under both sevoflurane and isoflurane anesthesia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16790647     DOI: 10.1213/01.ane.0000221188.09510.75

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  7 in total

Review 1.  Anesthetic considerations in diabetic patients. Part II: intraoperative and postoperative management of patients with diabetes mellitus.

Authors:  Yuji Kadoi
Journal:  J Anesth       Date:  2010-07-17       Impact factor: 2.078

2.  Differential effects of hyperventilation on cerebral blood flow velocity after tourniquet deflation during sevoflurane, isoflurane, or propofol anesthesia.

Authors:  Hiroshi Hinohara; Yuji Kadoi; Masanobu Ide; Masataka Kuroda; Shigeru Saito; Akio Mizutani
Journal:  J Anesth       Date:  2010-06-01       Impact factor: 2.078

3.  The comparative effects of sevoflurane versus isoflurane on cerebrovascular carbon dioxide reactivity in patients with previous stroke.

Authors:  Yuji Kadoi; Shigeru Saito; Ken-ichiro Takahashi
Journal:  J Anesth       Date:  2008-05-25       Impact factor: 2.078

4.  Evaluation of cerebrovascular carbon dioxide reactivity in patients with diabetes mellitus under sedative doses of propofol.

Authors:  Chikara Kawauchi; Yuji Kadoi; Hiroshi Hinohara; Fumio Kunimoto; Shigeru Saito
Journal:  J Anesth       Date:  2008-11-15       Impact factor: 2.078

5.  Sevoflurane anesthesia did not affect postoperative cognitive dysfunction in patients undergoing coronary artery bypass graft surgery.

Authors:  Yuji Kadoi; Fumio Goto
Journal:  J Anesth       Date:  2007-08-01       Impact factor: 2.078

6.  N-Acetylcysteine Restores Sevoflurane Postconditioning Cardioprotection against Myocardial Ischemia-Reperfusion Injury in Diabetic Rats.

Authors:  Jiefu Lin; Tingting Wang; Yalan Li; Mengxia Wang; Haobo Li; Michael G Irwin; Zhengyuan Xia
Journal:  J Diabetes Res       Date:  2015-12-13       Impact factor: 4.011

7.  Effect of sevoflurane on systemic and cerebral circulation, cerebral autoregulation and CO2 reactivity.

Authors:  Marianna Juhász; Levente Molnár; Béla Fülesdi; Tamás Végh; Dénes Páll; Csilla Molnár
Journal:  BMC Anesthesiol       Date:  2019-06-19       Impact factor: 2.217

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.